CAMKMT and neoplasm: Unlike other recently described KMT inhibitors, our compounds do not compete for SAM37 but instead simultaneously inhibit binding of G9a (also its closely related protein GLP) and DNMTs to their substrates reversibly, which may explain their selectivity, lack of off-target effects and therapeutic potential in different tumour types.